00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Commercial insurers covered just 7.8% of the country’s innovative drug and device market last year, as pricing, data and access barriers continue to constrain growth. Photo: IC photo
Despite efforts to ease pressure on state-run healthcare, commercial insurers covered just 7.8% of the country’s innovative drug and device market last year, as pricing, data and access barriers continue to constrain growth
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
Commercial insurers covered just 7.8% of the country’s innovative drug and device market last year, as pricing, data and access barriers continue to constrain growth. Photo: IC photo

As Chinese drugmakers churn out a record number of novel therapies, industry experts urge an overhaul of pricing, insurance and…

With more drugs in clinical trials than any other country, Chinese drugmakers are now shifting focus to the high-risk,…

The sales volume of China's innovative drugs and medical devices surged in 2025, while commercial insurance has become an…

The total value of China's innovative drug out-licensing deals exceeded $100 billion in the first half of the year, reaching a…

The country’s drug evaluation agency registered a jump in new drug and clinical trial applications, signaling a robust pivot…

Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink